Darwin Global Management, Ltd.
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Darwin Global Management, Ltd. reported 6 stock positions worth $3.8 billion. Its top holding was Insmed (INSM) at 68.3% of the portfolio, followed by Belite Bio Inc. - ADR (BLTE, 12.1%) and Abivax SA-ADR (ABVX, 9.3%). Compared with Q4 2025, it opened 3 new positions, sold out of 3, added to 2 and reduced 1. The biggest buy was a new position in Revolution Medicines (RVMD) and the biggest sale Insmed (INSM, shares −20%).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001839209
- Portfolio Value
- $3.8B (Q1 2026)
- SEC Filing
- 0001892688-26-000087 ↗ filed May 15, 2026
Holdings Value
Holdings 6 stocks · $3.8B
| INSM Insmed Inc. | 68.33% | 16,805,184 | $2.6B | Reduce -19.7% |
| BLTE Belite Bio Inc. - ADR | 12.10% | 3,057,412 | $456.1M | Add +1.0% |
| ABVX Abivax SA-ADR | 9.34% | 3,468,657 | $352.1M | Add +9.1% |
| RVMD Revolution Medicines Inc. | 5.44% | 2,211,018 | $205.0M | New |
| ROIV Roivant Sciences Ltd. | 4.76% | 6,797,300 | $179.5M | New |
| DNTH Dianthus Therapeutics Inc. | 0.04% | 17,357 | $1.5M | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $3.8B | RVMD, INSM, BLTE, ABVX, ROIV |
| Q1 2026 | 6 | $3.8B | INSM, BLTE, ABVX, RVMD, ROIV |
| Q4 2025 | 6 | $4.9B | INSM, BLTE, ABVX, CDTX, WVE |
| Q3 2025 | 5 | $3.6B | INSM, UTHR, ABVX, CDTX, QURE |
| Q2 2025 | 5 | $2.4B | INSM, VRNA, CDTX, MRUS, ALLO |
| Q1 2025 | 3 | $1.5B | INSM, VRNA, ALLO |
| Q4 2024 | 6 | $1.1B | INSM, JAZZ, VRNA, GERN, KROS |
| Q3 2024 | 5 | $1.2B | INSM, PCVX, GERN, KROS, SMMT |
| Q2 2024 | 9 | $859.5M | CYTK, INSM, PCVX, GERN, KROS |
| Q1 2024 | 12 | $751.2M | PCVX, NUVL, KROS, BHVN, ALPN |